CN109601804A - 一种绣球菌固体饮料 - Google Patents
一种绣球菌固体饮料 Download PDFInfo
- Publication number
- CN109601804A CN109601804A CN201811490434.9A CN201811490434A CN109601804A CN 109601804 A CN109601804 A CN 109601804A CN 201811490434 A CN201811490434 A CN 201811490434A CN 109601804 A CN109601804 A CN 109601804A
- Authority
- CN
- China
- Prior art keywords
- group
- parts
- powder
- sparassis crispa
- solid beverage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000272503 Sparassis radicata Species 0.000 title claims abstract description 76
- 239000007787 solid Substances 0.000 title claims abstract description 63
- 235000013361 beverage Nutrition 0.000 title claims abstract description 61
- 239000000843 powder Substances 0.000 claims abstract description 66
- 241000123107 Phellinus Species 0.000 claims abstract description 21
- 241000124033 Salix Species 0.000 claims abstract description 15
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 14
- 241000577951 Hydnum Species 0.000 claims abstract description 14
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000010931 gold Substances 0.000 claims abstract description 14
- 229910052737 gold Inorganic materials 0.000 claims abstract description 14
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 13
- 239000003765 sweetening agent Substances 0.000 claims abstract description 13
- 235000013312 flour Nutrition 0.000 claims abstract description 12
- 241000289669 Erinaceus europaeus Species 0.000 claims abstract 3
- 239000004376 Sucralose Substances 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 7
- 235000019408 sucralose Nutrition 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 15
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 14
- 235000012000 cholesterol Nutrition 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 description 44
- 239000008280 blood Substances 0.000 description 44
- 239000008103 glucose Substances 0.000 description 40
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 39
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 229920002472 Starch Polymers 0.000 description 21
- 235000019698 starch Nutrition 0.000 description 21
- 239000008107 starch Substances 0.000 description 21
- 244000060234 Gmelina philippensis Species 0.000 description 12
- 240000000588 Hericium erinaceus Species 0.000 description 12
- 235000007328 Hericium erinaceus Nutrition 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 11
- 235000004879 dioscorea Nutrition 0.000 description 9
- 235000002722 Dioscorea batatas Nutrition 0.000 description 8
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 8
- 240000001811 Dioscorea oppositifolia Species 0.000 description 8
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 8
- 241000233866 Fungi Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 8
- 229920001282 polysaccharide Polymers 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- -1 small molecule compound Chemical class 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical group C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 229960000346 gliclazide Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 241000233779 Cyclocarya paliurus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000123222 Hericium Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000004637 gastric cardia carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940032653 gliclazide 80 mg Drugs 0.000 description 1
- 150000002305 glucosylceramides Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- LGZXYFMMLRYXLK-UHFFFAOYSA-N mercury(2+);sulfide Chemical compound [S-2].[Hg+2] LGZXYFMMLRYXLK-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种绣球菌固体饮料,按重量份计,其由如下组分和含量组成:绣球菌粉40‑60份,桑黄粉5‑8份,猴头菇粉5‑10份,金耳粉20‑30份,青钱柳叶细粉3‑5份,山药粉10‑15份,甜味剂0‑16份。本发明绣球菌固体饮料具有降血糖和降低胆固醇的效果。
Description
技术领域
本发明涉及固体饮料领域,具体涉及一种绣球菌固体饮料。
背景技术
绣球菌(Sparassis Crispa)是一种珍贵的药食两用真菌,享“万菇之王”之美誉,有 效成分主要有蛋白质、多糖、麦角固醇、葡糖苷酰鞘氨醇、腺苷和其他一些小分子化合物等; 绣球菌中含有大量β-葡聚糖、抗氧化物质、维生素和矿物质,其超氧化物歧化酶和维生素E 的含量居菌藻类食物前列,具有提高免疫力、抗肿瘤、抗高血压、抗糖尿病等多种药理活性。 由于国内绣球菌的研究起步比较晚,目前基本上停在栽培技术方面,对于深加工的组合物产 品的研究较少,几乎是空白。
发明内容
有鉴于此,为解决上述技术问题,本发明的目的在于提出一种以绣球菌为主要原料的绣 球菌固体饮料,其具有降血糖和降低胆固醇的效果。
所采用的技术方案为:
一种绣球菌固体饮料,按重量份计,其由如下组分和含量组成:
绣球菌粉40-60份,桑黄粉5-8份,猴头菇粉5-10份,金耳粉20-30份,青钱柳叶细粉3-5份,山药粉10-15份,甜味剂0-16份。
在本技术方案中,
桑黄:为人工栽培的桑黄细粉。桑黄是一种珍贵的多年生大型药用木腐真菌,被现代人 称为“森林黄金”。桑黄菌提取物在抑制癌细胞转移和防止癌症手术后复发等的临床应用中 具有显著效果,是目前国际公认的生物治癌药剂中有效率最高的一种药用真菌。我国是野生 药用真菌出口大国,但目前对桑黄菌的研究还处于初步阶段,技术尚未成熟。
在我国,桑黄作为药用材料从汉朝开始,距今已经有2000多年的历史,最早的中医本草 学专著《神农本草经》就已经有关于“桑寄生”的药物疗效记载了,在中医著作《本草纲目》 中记载桑黄有“利五脏,宣肠胃气,排毒气”等药力功效。其主要活性成分是多糖类物质, 在医药领域具有重要的应用价值。桑黄的主要活性成分有多糖、黄酮,萜类物质等,其化学 成分还包括黑色素、过氧化酶、麦角甾醇、芳樟醇、脂肪酸类,芳香酸、原儿茶醛、丁香酸、 咖啡酸、柏皮素、香豆素等成分。桑黄作为一种重要药用菌有着非常广泛的药理作用,主要 表现在以下几个方面:降血糖作用、抗突变作用、增强机体的免疫力、抗肿瘤作用、抗纤 维化和脂质过氧化作用。
猴头菇:又称猴头菌,在医药上,猴头菌是一种贵重的良药。古时候就被作为难得的健身 补品,年老体弱者食用猴头菌,有滋补强身的作用。据记载,猴头菌性平味甘,有助消化, 利五脏、滋补身体等功能。现代医学研究证明,猴头菌中含有的多肽、多糖和脂肪族的酞胺 物质,有治疗癌症和有益人体健康的功效。对消化道***肿瘤有一定的抑制和医疗作用。对 消化不良、胃溃疡、胃窦炎、胃痛、胃胀等疾病有一定的疗效。民间还常把它用作治疗神经 衰弱的良药。经过深层发酵的培养物经分离提取所得,主要成分为多糖、氨基酸等,是猴菇 菌片、复方胃宁片等制剂的原料。广泛应用于医药领域。近年来的研究还表明,猴头还含有 多种糖类物质对癌细胞有明显的抑制作用。临床试验表明:猴头菌用于治胃溃疡、胃炎有效 率达86.6%,对胃癌、贲门癌和食道癌等消化道***恶性肿瘤,有效率达69.3%;其中疗效 显著者为15%,病人服用猴头菌后,自觉症状改善,食欲增添,疼痛缓解;对部分肿瘤患者, 还有提高细胞免疫功能,缩小肿块,延长生存期的良好效果。医药上的“猴头菌片”,就是 一种从猴头菌丝体中提炼出来的无毒性抗癌新药;已被广泛应用。还有用液体培养的猴头菌 深层发酵液,抗癌效果也很好。据研究,这种发酵液中脂溶性抗癌物质的含量大大高于固体 培养的菌丝体。为制取猴头菌抗癌新药提供一种简便而快速的方法。实验证明,癌症患者手 术后或化疗期间,多吃猴头菇可增强机体免疫力,缩小肿块,延长生存期:另外,猴头菇对 嗳气、冷酸、食欲不振、大便隐血也有良好的缓解作用。因它含有不饱和脂肪酸,可降低血 胆固醇,故为高血压和其他心血等疾病患者的理想保健食品。
金耳:因其颜色金黄,又称黄木耳,因其形似人脑,又称脑耳。金耳含有丰富脂肪,蛋 白质和磷、硫、锰、铁、镁、钙、钾等微量元素,是一种营养滋补品,并可作为药用。金耳 的滋补营养价值优于银耳、黑木耳等胶质菌类,是一种理想的高级筳宴佳肴和保健佳品。金耳子实体半球形,鲜时表面橙黄至橘红色,干后橙黄色至金黄色;干后收缩,坚硬,基本保持原状。金耳菌丝体多糖由鼠李糖、甘露糖、葡萄糖、半乳糖、岩藻糖组成;子实体多糖由葡萄糖、葡萄糖醛酸、甘露糖、木糖、鼠李糖组成。
药用功能:
①提高机体代谢机能,抑制肿瘤细胞的生长。
②调节机体代谢机能,改善机体营养状况,提高机体血红蛋白和血浆的含量。
③提高机体抗衰老、抗缺氧能力,降血糖、降血脂、降胆固醇。
④促进肝脏脂代谢,防止脂肪在肝脏积累,提高肝脏解毒功能。经常食用可有效地防病 健身,延缓衰老。
青钱柳:有机营养物青钱柳茶富含丰富的皂苷、黄酮、多糖等有机营养成分,能够有效 平衡人体糖代谢,从而达到降血糖,逆转并发症的养生效果;青钱柳复合茶含有大量的铁、 锌、硒、铬、锗、镁、钙等无机营养成分,还含有锰、铁、铜、铬、锌、硒、钒、锗等微量 元素,与糖代谢和胰岛素作用密切相关的元素Ni、Cr、V、Se的含量较高,能够协助胰岛素 发挥降血糖作用,并能改善糖耐量。医学研究发现,青钱柳芽叶含有一条神奇的原生态降糖 因子链,主要由两大原生态营养成分组成:无机营养成分跟有机营养成分,能够有效全面的调节人体糖代谢。
山药粉:滋补健身,延缓衰老、收涩固肠止泻、防治动脉硬化的冠心病、益气补气,止 咳定喘。
山药是补虚上品,对治疗糖尿病有较好疗效,其原因如下:
①.山药性味平和,不寒不燥,可充五脏,为治虚症要药。而糖尿病主要是阴虚燥热所致, 阴虚燥热消渴,可食山药,有益阴效果,所以山药可治疗糖尿病。
②.山药中所含的糖蛋白,在体内水解为蛋白质和糖类,有降低血糖的作用。山药所含的 淀粉酶具有帮助食物消化、水解淀粉为葡萄糖的作用。因此,对糖尿病有一定疗效,且胃肠 虚弱者也可食用。
③.山药既能补气,又能养阴,补而不滞,养而不腻,补脾气而益胃阴,为平补脾胃要药, 适用于糖尿病患者长期食用,对轻型糖尿病有显著疗效。
将绣球菌粉、桑黄粉、猴头菇粉、金耳粉、青钱柳叶细粉及山药粉均匀混合制成绣球菌 固体饮料,具有一定降血糖及降低胆固醇作用。
进一步地,绣球菌粉、桑黄粉、猴头菇粉、金耳粉、青钱柳叶细粉和山药粉的目数均≥ 500目。≥500目可以使粉的粒径较低,更容易混合均匀。
在本技术方案中,甜味剂作为选择组分,可以选择甜味剂的含量为0,即不添加甜味剂。 但甜味剂的作用在于,改善口感。为了改善口感,优选甜味剂的含量不为0。并优选所述甜 味剂为11.5-16份。
进一步地,所述甜味剂为木糖醇、麦芽糊精和三氯蔗糖中的一种或多种。
进一步地,所述甜味剂由如下组分和含量组成:
木糖醇8-10份,麦芽糊精3-5份,三氯蔗糖0.5-1份。
综上,本发明绣球菌固体饮料具有降血糖和降低胆固醇的效果。
附图说明
图1为实施例中各组小鼠的淀粉耐量及糖耐量曲线图。
图2为图1的曲线下面积(AUC,Area Under the Curve)图。
具体实施方式
下面对本发明做进一步详细的阐述。并详细记载动物实验,以表明本发明所具有的技术 效果。
实施例1
一种绣球菌固体饮料,按重量份计,其由如下组分和含量组成:
绣球菌粉40份,桑黄粉5份,猴头菇粉5份,金耳粉20份,青钱柳叶细粉3份,山药 粉10份,木糖醇8份,麦芽糊精3份,三氯蔗糖0.5份。
绣球菌粉、桑黄粉、猴头菇粉、金耳粉、青钱柳叶细粉和山药粉的目数均≥500目。
实施例2
一种绣球菌固体饮料,按重量份计,其由如下组分和含量组成:
绣球菌粉50份,桑黄粉7份,猴头菇粉7份,金耳粉25份,青钱柳叶细粉4份,山药 粉12份,木糖醇9份,麦芽糊精4份,三氯蔗糖0.7份。
绣球菌粉、桑黄粉、猴头菇粉、金耳粉、青钱柳叶细粉和山药粉的目数均≥500目。
实施例3
一种绣球菌固体饮料,按重量份计,其由如下组分和含量组成:
绣球菌粉60份,桑黄粉8份,猴头菇粉10份,金耳粉30份,青钱柳叶细粉5份,山药粉15份,木糖醇10份,麦芽糊精5份,三氯蔗糖1份。
绣球菌粉、桑黄粉、猴头菇粉、金耳粉、青钱柳叶细粉和山药粉的目数均≥500目。
实施例4绣球菌固体饮料动物实验
1.材料
1.1实验动物
清洁级ICR小鼠,由浙江省实验动物中心提供。动物饲养条件:温度22~24℃,湿度60%~ 80%,12h明暗交替,饮用水置于水瓶中自由饮用,饲料来源于浙江省实验动物中心。
1.2绣球菌固体饮料
杭州千岛湖兴宝菇业专业合作社提供实施例1-实施例3任一的绣球菌固体饮料。用饮用 水溶解配成相应浓度:150,300和600mg/mL,灌胃体积20ml/kg。
1.3试剂
生理盐水(0.9%),河北天成药业股份有限公司,规格100ml/瓶,批号D18021104。链 脲佐菌素(S0130),sigma公司,批号WXBC2044V,使用前用0.1mol/L柠檬酸缓冲液(pH=4.5) 配成1%的链脲佐菌素(STZ)溶液。四氧嘧啶(阿脲一水合物98%),麦克林公司,批号C10150830, 使用前用生理盐水配制。盐酸二甲双胍片,施维雅制药有限公司,规格0.5g/片,批号1112012。 格列齐特缓释片,施维雅制药有限公司,规格30mg/片,批号2012270。葡萄糖(批号 20180402137)、甘油三酯(批号20180918)和总胆固醇(批号20180919),均购于南京建 成有限公司。
1.4仪器
BSA124S电子天平,德国Sartorius公司;1-14K高速离心机:德国Sigma公司;血糖仪, 强生公司;BA-88A半自动生化仪,迈瑞医疗国际有限公司;iMark酶标仪,美国伯乐公司。
2.方法与结果
2.1对二型糖尿病小鼠模型的降血糖作用
雄性ICR小鼠60只,18-22g,适应性喂养1周,随机选10只为正常对照组,全程给基础 饲料,其余50只给予高糖高脂饲料(配方:10%猪油、10%蔗糖、2%胆固醇、1%猪胆盐、77%基础饲料),两周后连续3天腹腔注射链脲霉素(STZ)溶液45mg/kg,72h后,禁食 不禁水12h断尾采血检测其空腹血糖值,将造模成功的糖尿病小鼠50只随机分成5组,每组 10只,分别为模型对照组、阳性对照组、绣球菌固体饮料150,300和600mg/kg剂量组。 除正常对照组10只小鼠给普通饲料外,其余均给高脂饲料喂养。每天定时灌胃给药,连续灌 胃3周。阳性对照组按200mg·kg-1二甲双胍灌胃给药。绣球菌固体饮料各组分别按相应剂 量灌胃。正常对照组与模型组对照组给予等量生理盐水。实验期间每天观察记录小鼠毛色、 精神状态、行为活动和感染现象,每周测体重各1次。每周剪尾测定1次空腹血糖,给药2 周时进行1次糖耐量试验,末次给药后次日股动脉取血,测定血清胆固醇(TC)、甘油三酯(TG)、 血糖(GLU)。
若降血糖生化指标有效,则在小鼠取血处死后,取胰腺组织,用中性甲醛固定,石蜡包 埋切片,HE染色,进行病理组织学光镜检查,观察胰腺组织形态学变化。
结果如下:
表1各组小鼠体重变化(n=10)
注:**p<0.01与正常组相比
如表1,与正常组相比,高脂高糖饲料联合STZ造模后,各组体重均出现升高(P<0.01)。 给药3周期间,各组体重无统计学差异。在给药3周时,二甲双胍和绣球菌固体饮料300,600 mg/kg组体重增长减慢,略低于模型组和正常组。
如表2所示,造模后,与正常组相比,其余各组血糖升高,具有统计学差异(P<0.05)。 给药1周后,各组血糖仍在升高,与正常组相比具有显著性差异(P<0.05),给药2周后,各 给药组血糖下降,均低于模型组,但无统计学差异。给药3周后,模型组小鼠血糖与正常组相 比有显著性差异(P<0.01),二甲双胍和绣球菌固体饮料150,300mg/kg剂量组小鼠血糖下降, 与模型组相比有统计学意义(P<0.01,P<0.05)。
表2各组小鼠血糖变化(n=10)
注:*p<0.05,**p<0.01与正常组相比,#p<0.05,##p<0.01与模型组相比
表3绣球菌固体饮料对口服淀粉耐量的影响(n=10)
注:**p<0.01与正常组相比,#p<0.05,##p<0.01与模型组相比
如表3所示,给淀粉0.5h至1h后,各组血糖升高,模型组与正常组相比有显著性差异 (P<0.01),各给药组血糖值均低于模型组。给淀粉2h时,绣球菌固体饮料150mg/kg组与模 型组有显著性差异(P<0.05)。给淀粉3h时,绣球菌固体饮料150,300mg/kg组与模型组有显著性差异(P<0.05)。与正常组相比,模型组小鼠血糖AUC显著升高(P<0.05)。与模型组 相比,各给药组小鼠血糖AUC下降,其中绣球菌固体饮料150mg/kg组有统计学差异(P<0.05)。
表4绣球菌固体饮料对血清中甘油三酯TG和总胆固醇TC的影响(n=10)
注:**p<0.01与正常组相比,#p<0.05,##p<0.01与模型组相比
如表4所示,各组小鼠血清中甘油三酯含量无明显差别。而模型组小树总胆固醇升高,与 正常组相比有统计学差异(P<0.01)。与模型组相比,各给药组小鼠总胆固醇含量下降,具 有统计学差异(P<0.01,P<0.05)。
因此,绣球菌固体饮料150和300mg/kg组对链脲霉素二型糖尿病小鼠模型具有一定降血 糖及降低胆固醇作用。
22绣球菌固体饮料对正常小鼠淀粉以及葡萄糖负荷糖耐量的影响
雄性ICR小鼠50只,按体重随机分为5组,每组10只,正常对照组灌胃给予饮用水,阳 性对照组灌胃给予格列齐特80mg/kg,其余3组灌胃给予绣球菌固体饮料150,300和600mg·kg-1分别灌胃10天,每天1次。于末次给药前禁食12h,采血测定空腹血糖,末次给药后0.5h尾静 脉采血后即给以淀粉3.0g/kg灌胃,于给淀粉后0.5、1.0、1.5、2.0h尾静脉采血测血糖含量。 前述各组小鼠按各剂量再连续给药3天,于末次给药前禁食12h,尾静脉采血测定空腹血糖, 给药后05h采血,给以葡萄糖2.5g/kg灌胃,于给葡萄糖后0.5、1.0、1.5、2.0h尾静脉采血 测血糖含量。曲线下面积(AUC)计算法:mmol/L=(1/2A+B+C+D+1/E)/2(A、B、C、D、E分别 为给药后0.5h,给淀粉(葡萄糖)后0.5、1.0、1.5、2.0h的血糖值)。
结果如下:
如表5所示,在实验期间,与正常组小鼠相比,各给药组小鼠体重无显著性差异。如表6 和7所示,与正常组小鼠相比,给药组小鼠空腹血糖呈现下降趋势,其中绣球菌固体饮料300 mg/kg尤为显著(P<0.05)。在给药0.5h后,正常组和各绣球菌固体饮料组血糖与空腹时相比 均出现升高的趋势,但各绣球菌固体饮料组和阳性组均低于正常组,其中阳性组,绣球菌固 体饮料150,300mg/kg有统计学差异(P<0.05,P<0.01)。
表5各组小鼠体重变化(n=10)
表6绣球菌固体饮料对口服淀粉耐量的影响(n=10)
注:*p<0.05,**p<0.01与正常组相比
续表6绣球菌固体饮料对口服淀粉耐量的影响(n=10)
注:*p<0.05,**p<0.01与正常组相比
表7绣球菌固体饮料对口服葡萄糖耐量的影响(n=10)
注:*p<0.05,**p<0.01与正常组相比
续表7绣球菌固体饮料对口服葡萄糖耐量的影响(n=10)
注:*p<0.05,**p<0.01与正常组相比
如表6所示,在口服淀粉后,各组血糖均出现升高。正常组在0.5至1h平均血糖值达10. 5mmol/L以上,处于峰值,1.5h开始下降,2h时降至8.53mmol/L,阳性组和其他各组在1h达到 峰值,但均低于正常组,1.5h绣球菌固体饮料150,300mg/kg与正常组相比有显著性差异 (P<0.05,P<0.01),2h时绣球菌固体饮料各组降至8.0mmol/L以下,阳性组降至6.35mmol/L, 与正常组相比,绣球菌固体饮料150,300mg/kg组以及阳性组AUC明显低于正常组,具有统计 学意义(P<0.05,P<0.01)。
如表7所示,在口服葡萄糖后,各组血糖均出现升高,0.5h时达峰值。正常组在0.5h时平 均血糖值达15.0mmol/L以上,1h开始下降,2h时降至8.45mmol/L,阳性组和其他各组在0.5h 时血糖均低于正常组,1.0h后出现下降,在1.5h时绣球菌固体饮料150,300mg/kg组血糖与正 常组相比有显著性差异(P<0.05,P<0.01),2h时绣球菌固体饮料各组降至7.5mmol/L以下, 阳性组降至6.43mmol/L,阳性组和绣球菌固体饮料150mg/kg剂量组与正常组相比有显著性 差异(P<0.05,P<0.01)。与正常组相比,绣球菌固体饮料150,300mg/kg剂量组AUC明显低于 正常组,具有统计学意义(P<0.05,P<0.01)。
因此,绣球菌固体饮料150和300mg/kg组对正常小鼠葡萄糖耐量和淀粉糖耐量具有改善 作用。
3绣球菌固体饮料对四氧嘧啶性糖尿病小鼠的降糖以及淀粉耐量试验
雄性ICR小鼠70只,禁食12h后尾静脉注射四氧嘧啶100mg/kg,3d后,禁食5h剪尾尖取血, 测血糖。选取造模成功的小鼠,分组及给药如下:正常组、模型组、格列齐特(80mg/kg)、绣 球菌固体饮料(150,300,600mg/kg)三剂量组。各组灌胃给药30天,每天1次,每隔2周给 药后禁食5h尾静脉采血测血糖。前述各组小鼠按各剂量再连续给药10d,于末次给药前禁食2h, 尾静脉采血后即给药,0.5h后即给以淀粉3.0g/kg灌胃,于给淀粉后1.0、2.0、3.0h尾静脉采 血测血糖含量。曲线下面积计算:mmol/L=I/2A+B+C+1/2D,A、B、C、D分别为末次给药前禁 食2h后的血糖值,给淀粉后1.0、2.0、3.0h的血糖值。
结果如下:
如表8所示,与正常组相比,各组体重减轻,有统计学差异(P<0.01),与模型组相比, 各给药组体重下降,绣球菌固体饮料各组具有显著性差异(P<0.05)。
如表9所示,与正常组相比,造模后各组血糖升高,达22.0mmol/l以上,有统计学差异 (P<0.01),在给药2周后,各给药组血糖下降,绣球菌固体饮料150mg/kg剂量组与模型组相 比,具有显著性差异(P<0.05)。在给药4周后,绣球菌固体饮料150,300mg/kg剂量组与模型组相比,具有显著性差异(P<0.05,P<0.01)。与2周时相比,给药4周血糖回升,均与正 常组相比有统计学差异(P<0.05,P<0.01)。
如表10、图1和图2所示,口服淀粉后,1h时除正常组外,各组血糖到达30mmol/l左右, 3h时,阳性组下降至22.3mmol/l,绣球菌固体饮料各剂量组均高于25.mmol/l。各组AUC均明 显高于正常组,有统计学差异(P<0.01).阳性组和绣球菌固体饮料600mg/kg剂量组AUC低于 模型组,具有统计学意义(P<0.05)。
表8各组小鼠体重变化(n=10)
注:**p<0.01与正常组相比,#p<0.05与模型组相比
表9各组小鼠血糖变化(n=10)
注:**p<0.01与正常组相比,#p<0.05,##p<0.01与模型组相比
表10绣球菌固体饮料对口服淀粉耐量的影响(n=10)
注:*p<0.05,**p<0.01与正常组相比,#p<0.05与模型组相比
因此,绣球菌固体饮料150,300mg/kg对四氧嘧啶性糖尿病小鼠具有一定降糖作用,绣球 菌固体饮料600mg/kg对四氧嘧啶性糖尿病小鼠淀粉耐量有一定改善作用。
需要说明的是,表1-表10中,“粉低”表示150mg/kg的绣球菌固体饮料,“粉中”表示300mg/kg的固体饮料,“粉高”表示600mg/kg的绣球菌固体饮料。
上文所列出的一系列的详细说明仅仅是针对本发明的可行性实施例的具体说明,它们并 非用以限制本发明的保护范围,凡未脱离本发明技艺精神所作的等效实施例或变更均应包含 在本发明的保护范围之内。
Claims (5)
1.一种绣球菌固体饮料,其特征在于,按重量份计,其由如下组分和含量组成:
绣球菌粉40-60份,桑黄粉5-8份,猴头菇粉5-10份,金耳粉20-30份,青钱柳叶细粉3-5份,山药粉10-15份,甜味剂0-16份。
2.根据权利要求1所述的绣球菌固体饮料,其特征在于,绣球菌粉、桑黄粉、猴头菇粉、金耳粉、青钱柳叶细粉和山药粉的目数均≥500目。
3.根据权利要求1所述的绣球菌固体饮料,其特征在于,所述甜味剂为11.5-16份。
4.根据权利要求1所述的绣球菌固体饮料,其特征在于,所述甜味剂为木糖醇、麦芽糊精和三氯蔗糖中的一种或多种。
5.根据权利要求4所述的绣球菌固体饮料,其特征在于,所述甜味剂由如下组分和含量组成:
木糖醇8-10份,麦芽糊精3-5份,三氯蔗糖0.5-1份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811490434.9A CN109601804A (zh) | 2018-12-06 | 2018-12-06 | 一种绣球菌固体饮料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811490434.9A CN109601804A (zh) | 2018-12-06 | 2018-12-06 | 一种绣球菌固体饮料 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109601804A true CN109601804A (zh) | 2019-04-12 |
Family
ID=66007400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811490434.9A Withdrawn CN109601804A (zh) | 2018-12-06 | 2018-12-06 | 一种绣球菌固体饮料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109601804A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111956736A (zh) * | 2020-08-04 | 2020-11-20 | 浙江省农业科学院 | 一种以绣球菌为主的降血糖组合物及其制备方法和应用 |
-
2018
- 2018-12-06 CN CN201811490434.9A patent/CN109601804A/zh not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111956736A (zh) * | 2020-08-04 | 2020-11-20 | 浙江省农业科学院 | 一种以绣球菌为主的降血糖组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101160943B1 (ko) | 상황버섯 균사체와 산삼 배양근 혼합 추출물을 유효성분으로 함유하는 암 예방 및 개선용 건강기능 식품 조성물 | |
CN101491334B (zh) | 一种具有增强免疫力功能的保健食品 | |
CN107114783A (zh) | 一种增强免疫及辅助肿瘤恢复的高硒营养补充剂 | |
CN103083535A (zh) | 一种黑茶组合物,以及在减肥领域的应用 | |
CN106244371B (zh) | 一种降血糖黄精葡萄保健酒及其生产工艺 | |
CN102697035A (zh) | 虫草褔寿丹 | |
CN102526479B (zh) | 一种增强免疫力、降血糖功能的保健药物 | |
CN101579120A (zh) | 一种具有减肥功能的营养食品及其制备方法 | |
CN102008516B (zh) | 一种***的超微粉中药 | |
CN111035649A (zh) | 一种nmn+glp复配营养补充剂及其制备方法和应用 | |
Yampolsky et al. | Apricot (lat. Prunus armeniaca Lin.) | |
KR101062172B1 (ko) | 버섯 발효인삼 분말을 함유하는 항암용 건강식품 | |
CN106616947A (zh) | 一种蛹虫草组合物 | |
CN102657304B (zh) | 一种具有促进消化和缓解体力疲劳双功能的保健食品 | |
CN103181561B (zh) | 一种具有秋季养生保健作用的保健食品及其制备方法 | |
CN109481589A (zh) | 一种治疗肺癌的排毒抗癌胶囊及食疗抗癌的制备方法 | |
CN109090604A (zh) | 一种具有辅助降血糖功能的组合物、保健食品及其制备方法 | |
CN109601804A (zh) | 一种绣球菌固体饮料 | |
CN114365844B (zh) | 一种调节肠道菌群、提高肠道免疫的竹荪复方保健食品及其制备方法 | |
CN103053638A (zh) | 一种恢复胰岛功能消除胰岛素抵抗的面粉及其制法 | |
CN103239470B (zh) | 一种含鸡腿蘑多糖和香菇多糖的双菇多糖组合物及其制法和用途 | |
CN106511915B (zh) | 一种复方中药组合物在抑制皮肤黑色素瘤肺转移药物中的应用 | |
CN105285284A (zh) | 一种灰树花食用菌压片糖果及其制备方法 | |
CN107468952A (zh) | 一种具有辅助降血糖功能的药食同源组合物的制备方法 | |
CN100562325C (zh) | 一种***的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190412 |
|
WW01 | Invention patent application withdrawn after publication |